Pipeline

We turn science into medicine

We are inspired by the power of the human immune system to fight diseases. We use our expertise to seek new and transformative antibody technologies and have a proven track record of discovering and developing innovative medicines targeting cancer and other serious diseases.

We also have a pipeline of antibody therapeutics that includes investigational medicines in clinical development, and in-house and partnered pre-clinical programs.

products

Our groundbreaking accomplishments

  • 8

    Approved therapies incorporating Genmab innovation

  • 4

    Proprietary Genmab technologies

  • ~20

    Products in clinical development incorporating Genmab innovation

Products in development

At Genmab, we are inspired by nature and understand how antibodies work. We are proud to invest in and advance a robust pipeline of differentiated antibody candidates that are at the forefront of the industry. This is accomplished by leveraging our own cutting-edge scientific capabilities, innovative scientific approach, translational medicine laboratory expertise and strategic partnerships.

Our deep scientific understanding of antibodies, including which patients will benefit most from them, helps define Genmab as a leading biotechnology company.

The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.

Filters

Product Pipeline

Genmab proprietary products1
The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.

  • Epcoritamab (DuoBody®)

    Partnership: AbbVie Inc.

    Target: CD3, CD20

    Relapsed/refractory diffuse large B-cell lymphoma:

    • Pre-clinical
    • 1
    • 2
    • 3

    Relapsed/refractory follicular lymphoma:

    • Pre-clinical
    • 1
    • 2
    • 3

    First Line Diffuse large B-cell lymphoma:

    • Pre-clinical
    • 1
    • 2
    • 3

    B-cell non-Hodgkin lymphoma:

    • Pre-clinical
    • 1
    • 2
    • 3

    Relapsed/refractory chronic lymphocytic leukemia and Richter’s Syndrome:

    • Pre-clinical
    • 1
    • 2
    • 3

    Aggressive mature B-cell neoplasms in pediatric patients:

    • Pre-clinical
    • 1
    • 2
    • 3

    Overview

    Epcoritamab (DuoBody®-CD3xCD20) is an investigational proprietary bispecific antibody created using Genmab’s DuoBody technology, jointly owned by Genmab and AbbVie Inc. It targets CD20 on the B-cells, a validated target that is expressed in a wide variety of B-cell malignancies.

    Clinical Trials

    Epcoritamab (DuoBody-CD3xCD20) is currently under investigation in multiple ongoing clinical studies including a phase 3 study for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). In addition, Phase 1/2 clinical studies in B-cell non-Hodgkin lymphoma (B-NHL), including relapsed/refractory chronic lymphocytic leukemia (CLL), and in combination with standard of care therapies for B-NHL are ongoing.

    More info

  • Tisotumab vedotin

    Partnership: Seagen Inc.

    Target: Tissue Factor

    Cervical cancer:

    • Pre-clinical
    • 1
    • 2
    • 3

    Solid tumors:

    • Pre-clinical
    • 1
    • 2
    • 3

    Overview

    Tisotumab vedotin is an antibody-drug conjugate (ADC) targeted to tissue factor (TF), a protein involved in tumor growth, angiogenesis, and metastasis.1,2 It is composed of Genmab’s human monoclonal antibody (mAb) that binds to TF and Seagen’s ADC technology that utilizes a cleavable linker and the cytotoxic drug monomethyl auristatin E (MMAE).3 TF is a transmembrane protein that is an initiator of the extrinsic pathway of coagulation, and is involved in angiogenesis, cell adhesion, motility, and cell survival. 3, 4, 5

    Clinical Trials

    Tisotumab vedotin is being investigated in clinical studies in a variety of solid tumors.

    References

    1. Förster, et al. Tissue factor and tumor: Clinical and laboratory aspects. Clinica Chimica Acta, Volume 364, Issues 1–2, 2006, Pages 12-21, ISSN 0009-8981, https://doi.org/10.1016/j.cca.2005.05.018.
    2. van den Berg, et al. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood. 2012 Jan 26;119(4):924-32. Doi: 10.1182/blood-2011-06-317685. Epub 2011 Nov 7. PMID: 22065595.
    3. Chu AJ. Tissue factor, blood coagulation, and beyond: an overview. Int J Inflam.2011;2011:36784. Doi:10.4061/2011/367284.
    4. Ruf W. Tissue factor and cancer. Thromb Res.2012;130:S84-S87.
    5. Cimmino G, Cirillo P. Tissue factor: newer concepts in thrombosis and its role beyond thrombosis and hemostasis. Cardiovasc Diagn Ther. 2018 Oct;8(5):581-593. Doi: 10.21037/cdt.2018.10.14. PMID: 30498683; PMCID: PMC6232348.

  • Acasunlimab (previously known as GEN1046/BNT311)

    Partnership: BioNTech

    Target: PD-L1, 4-1BB

    Non-small cell lung cancer:

    • Pre-clinical
    • 1
    • 2
    • 3

    Advanced endometrial cancer:

    • Pre-clinical
    • 1
    • 2
    • 3

    Solid tumors:

    • Pre-clinical
    • 1
    • 2
    • 3

    Overview

    Acasunlimab (previously known as GEN1046/BNT311) is an investigational proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab’s DuoBody technology. It is being co-developed by Genmab under an agreement in which the companies share all costs and future profits for the product on a 50:50 basis. Acasunlimab is designed to elicit an anti-tumor immune response by simultaneous and complementary PD-L1 blockade and conditional 4-1BB stimulation, using inert DuoBody IgG1 antibody format.

    Clinical Trials

    A Phase 1/2 clinical study of Acasunlimab in solid tumors and two Phase 2 clinical studies of Acasunlimab are ongoing: as a single agent or in combination with another anti-cancer therapy in relapsed/refractory metastatic non-small cell lung cancer and in combination with pembrolizumab in advanced endometrial cancer.

    More info

  • GEN1042/BNT312 (DuoBody®)

    Partnership: BioNTech

    Target: CD40, 4-1BB

    Solid tumors:

    • Pre-clinical
    • 1
    • 2
    • 3

    Overview

    GEN1042/BNT312 (DuoBody®-CD40x4-1BB) is an investigational proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab’s DuoBody technology. It is being co-developed under an agreement in which the companies share all costs and future profits for the product on a 50:50 basis. CD40 and 4-1BB were selected as targets to enhance both dendritic cells (DC) and antigen-dependent T-cell activation, using an inert DuoBody format.

    Clinical Trials

    Phase 1/2 clinical studies of GEN1042/BNT312 in solid tumors are ongoing.

    More info

  • GEN3014 (HexaBody®)

    Partnership: 

    Target: CD38

    Hematological malignancies:

    • Pre-clinical
    • 1
    • 2
    • 3

    Overview

    GEN3014 (HexaBody®-CD38) is an investigational human CD38 monoclonal antibody incorporating Genmab’s HexaBody technology. In June 2019, Genmab entered into an exclusive worldwide license and option agreement with Janssen Biotech Inc. to develop and commercialize GEN3014.

    Clinical Trials

    A phase 1/2 clinical study of GEN3014 in hematological malignancies is ongoing.

    More info

  • GEN1047 (DuoBody®)

    Partnership: 

    Target: CD3, B7H4

    Solid Tumors:

    • Pre-clinical
    • 1
    • 2
    • 3

    Overview

    GEN1047 (DuoBody®-CD3xB7H4) is an investigational proprietary bispecific antibody created using Genmab’s DuoBody technology. B7H4 is an immune checkpoint protein expressed on malignant cells in various solid cancers including breast, ovarian and lung cancer. In preclinical studies, GEN1047 was shown to induce T-cell mediated cytotoxicity of B7H4-positive tumor cells.

    Clinical Trials

    A phase 1/2 clinical study of GEN1047 in solid tumors is ongoing.

    More info

  • GEN1053/BNT313 (HexaBody®)

    Partnership: BioNTech

    Target: CD27

    Solid Tumors:

    • Pre-clinical
    • 1
    • 2
    • 3

    Overview

    GEN1053/BNT313 is an investigational CD27 antibody that utilizes Genmab’s HexaBody® technology, specifically engineered to form an antibody hexamer (a formation of six antibodies) upon binding its target on the cell membrane of the T-cells. As part of the strategic partnership with BioNTech, the companies will jointly develop and commercialize GEN1053/BNT313.

    Clinical Trials

    A Phase 1/2 clinical study of GEN1053/BNT313 in solid tumors is ongoing.

    More info

  • GEN1056/BNT322

    Partnership: BioNTech

    Target: Undisclosed

    Solid Tumors:

    • Pre-clinical
    • 1
    • 2
    • 3

    Overview

    GEN1056/BNT322 is an investigational antibody-based medicine being co-developed by Genmab and BioNTech for the treatment of solid tumors.

    Clinical Trials

    Phase 1 clinical study of GEN1056/BNT322 in patients with advanced solid tumors is ongoing.

    More info

  • GEN3017 (DuoBody®)

    Partnership: 

    Target: CD3xCD30

    Hematological malignancies:

    • Pre-clinical
    • 1
    • 2
    • 3

    Overview

    GEN3017 (DuoBody®-CD3xCD30) is an investigational proprietary bispecific antibody created using Genmab’s DuoBody technology. CD30 is highly expressed in multiple hematologic malignancies, including classical Hodgkin lymphoma and anaplastic large cell lymphoma. In pre-clinical studies, GEN3017 induced potent T-cell mediated cytotoxicity of CD30-expressing tumor cells in vitro, which was associated with induction of CD4+ and CD8+ T-cell activation, proliferation and cytokine production.

    Clinical Trials

    A phase 1/2 clinical study of GEN3017 in relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma is ongoing.

    More info

Products created by Genmab2

  • Daratumumab

    Partnership: Janssen Biotech, Inc.

    Target: CD38

    Overview

    Daratumumab is a human IgG1k monoclonal antibody (mAb). Janssen Biotech, Inc. (Janssen) has an exclusive worldwide license from Genmab to develop, manufacture and commercialize daratumumab.

    A clinical development program for daratumumab is ongoing by Janssen.

  • Ofatumumab

    Partnership: Novartis Pharma AG

    Target: CD20

    Overview

    Ofatumumab is a human monoclonal antibody which targets an epitope in the CD20 molecule encompassing parts of the small and large extracellular loops. 

    Novartis Pharma AG is responsible for the development and commercialization of ofatumumab. 

  • Teprotumumab

    Partnership: Horizon Therapeutics, under a license from Roche

    Target: IGF-1R

    Overview

    Teprotumumab is a fully human antibody created by Genmab under a collaboration with Roche. Commercialization of the product is now being conducted by Horizon Therapeutics (Horizon) under a sublicense from Roche.

    Horizon is responsible for the development of teprotumumab.

Partner-owned products incorporating Genmab’s innovation, Phase 2 and later3

  • Amivantamab

    Partnership: Janssen Biotech, Inc.

    Target: EGFR, cMet

    Overview

    Amivantamab is a fully human bispecific antibody. In July 2012, Genmab entered into a collaboration with Janssen Biotech, Inc. (Janssen) to create and develop bispecific antibodies using Genmab’s DuoBody® technology platform.

    Janssen is responsible for the development and commercialization of amivantamab.

  • Inclacumab

    Partnership: Pfizer

    Target: P-selectin

    Overview

    Inclacumab is an investigational human monoclonal antibody against P-selectin. Inclacumab was created under a collaboration with Roche.

    Pfizer is responsible for the development and commercialization of Inclacumab.

  • Teclistamab (JNJ-64007957)

    Partnership: Janssen Biotech, Inc.

    Target: BCMA, CD3

    Overview

    Teclistamab (JNJ-64007957) is a bispecific antibody. In July 2012, Genmab entered into a collaboration with Janssen Biotech, Inc. (Janssen) to create and develop bispecific antibodies using Genmab’s DuoBody® technology platform.

    Janssen is responsible for the discovery, development and commercialization of teclistamab.

  • Talquetamab (JNJ-64407564)

    Partnership: Janssen Biotech, Inc.

    Target: GPRC5D, CD3

    Overview

    Talquetamab (JNJ-64407564) is a bispecific antibody. In July 2012, Genmab entered into a collaboration with Janssen Biotech, Inc. (Janssen) to create and develop bispecific antibodies using Genmab’s DuoBody® technology platform.

    Janssen is responsible for the development and commercialization of talquetamab.

  • Camidanlumab tesirine

    Partnership: ADC Therapeutics

    Target: CD25

    Overview

    Camidanlumab tesirine (ADCT-301) is an investigational antibody-drug conjugate (ADC) combining Genmab’s HuMax®-TAC antibody and ADC Therapeutics’ PBD-based warhead and linker technology. Camidanlumab tesirine targets CD25, which is expressed on a variety of hematological tumors and shows limited expression on normal tissues, except for regulatory T cells (Tregs), which are known to be immunosuppressive.

    ADC therapeutics is responsible for the development of camidanlumab tesirine.

  • Mim8

    Partnership: Novo Nordisk

    Target: FIXa, FX

    Overview

    Mim8 is an investigational next-generation factor VIII mimetic human bispecific antibody. Mim8 is a highly potent molecule bridging factor IXa (FIXa) and factor X (FX) in development for subcutaneous treatment of people with hemophilia A.

    Novo Nordisk is responsible for the development of Mim8.

  • Ordesekimab

    Partnership: Provention Bio

    Target: IL-15

    Overview

    Ordesekimab is an investigational human monoclonal antibody that binds to Interleukin-15 (IL-15), a cytokine molecule appearing early in the cascade of events that ultimately leads to inflammatory disease.

    Amgen and Provention Bio announced a licensing and co-development agreement for ordesekimab (also known as PRV-015 or AMG 714).

  • Lu AF82422

    Partnership: H. Lundbeck A/S

    Target: alpha-Synuclein

    Overview

    Lu AF82422 is an investigational human monoclonal antibody (mAb) targeting the toxic alpha-synuclein protein known to be a pathological hallmark of MSA. It is believed to target the underlying biology of the disease and may potentially slow or stop the progression of MSA.

    H. Lundbeck A/S is responsible for the development of Lu AF82422.

  • Multiple active pre-clinical programs

    Partnership: 

    Target: 

    Partnered & proprietary programs (DuoBody®, DuoHexaBody® and HexaBody®):

    • Pre-clinical
    • 1
    • 2
    • 3

1 Tisotumab vedotin – 50:50 partnership with Seagen Inc.; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB – 50:50 partnership with BioNTech; Epcoritamab – 50:50 partnership with AbbVie Inc.

2 Out-licensed products marketed by partner.

3 Products under development by a third-party incorporating Genmab technology and innovation.

COM-GL-Pipeline-0000034

  • Putting our expertise to work

    See how we put our in-depth knowledge of antibody biology into action

    Learn about our science

  • Innovation for the future

    Leveraging technologies to create first- or best-in-class products

    See our technologies

  • Partners in science

    See how our collaborative spirit drives our partnerships

    See current partners

You are now leaving Genmab.com to go to our collaborator’s website. If you continue, we encourage you to read the website’s privacy and cookie policy.

Continue

Back